AI Article Synopsis

  • Raised blood pressure (BP) is a significant risk factor for cardiovascular issues and mortality, with a global campaign called May Measurement Month launched to raise awareness and encourage BP screenings since 2017 in Australia.
  • Over three years, about 10,046 adults were screened, revealing that 31% had hypertension, with only 48.5% being aware of their condition and 44.4% actively taking medication.
  • The findings highlighted a concerning lack of awareness and poor control of hypertension in Australia, which are below global averages, indicating the need for collective action to improve treatment and management rates.

Article Abstract

Background: Raised blood pressure (BP) remains the single most important modifiable risk factor contributing to cardiovascular and all-cause mortality in Australia and worldwide. May Measurement Month , a global BP measurement and screening campaign initiated by the International Society of Hypertension and carried out in Australia since its inception in 2017, aimed at obtaining standardized BP measurements from members of the community to increase awareness of high BP and its associated risks.

Method: Adults participants (≥18 years) were recruited through opportunistic sampling across Australia during the month of May in 2017, 2018 and 2019. Trained volunteers recorded BP readings in a standardized manner and collected data on demographic, lifestyle factors and comorbidities. Hypertension was defined as SBP of at least 140 mmHg, or DBP of at least 90 mmHg, or taking antihypertensive medication. Data were collated centrally and analysis was carried out using regression models to evaluate the associations between BP and participant characteristics.

Results: A total of 10 046 participants were screened, of whom 3097 (31.0%) had hypertension, only 48.5% were aware of their condition and 44.4% were taking antihypertensive medication. Of those taking antihypertensive medication, 53.2% were controlled to less than 140/90 mmHg, whereas the remaining 46.8% of participants had BP of at least 140/90 mmHg suggestive of inadequately treated hypertension.

Conclusion: Consecutive data obtained over a 3-year period in Australia demonstrated stagnating awareness, treatment and control rates with the latter two being substantially lower than global rates and those in other high-income countries. Concerted efforts from all stakeholders will be required to help overcome the unacceptably poor rates of BP treatment and control in Australia.

Download full-text PDF

Source
http://dx.doi.org/10.1097/HJH.0000000000003379DOI Listing

Publication Analysis

Top Keywords

antihypertensive medication
12
blood pressure
8
control australia
8
10 046 participants
8
measurement month
8
treatment control
8
australia
6
stagnating rates
4
rates blood
4
pressure control
4

Similar Publications

Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a novel class of medications characterized by their dual action on major cardiorenal regulators, specifically the renin-angiotensin system (RAS) and the natriuretic peptide (NP) system. Sacubitril/valsartan, a pioneering ARNI, has demonstrated strong antihypertensive effect as well as superior efficacy in preserving renal function compared to RAS inhibitors in heart failure patients with reduced ejection fraction. Here, we gathered evidence on the impact of sacubitril/valsartan on the preservation of kidney function in patients with cardiorenal syndrome (CRS).

View Article and Find Full Text PDF

Long-acting nifedipine in the management of essential hypertension: a review for cardiologists.

Am J Cardiovasc Dis

December 2024

J.B. Chemicals and Pharmaceuticals Ltd. Cnergy It Park, Unit A, Appasaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai, Maharashtra 400025, India.

Calcium channel antagonists, specifically long-acting nifedipine formulations, play a crucial role in treating hypertension and angina. Originally used for angina, nifedipine has been widely employed as an antihypertensive medication for over 40 years. It offers rapid action and oral bioavailability with minimal maternal or fetal side effects, making it suitable for treating hypertensive crises during pregnancy.

View Article and Find Full Text PDF

Persistent Gingival Bleeding Related to Periodontal Disease.

Cureus

January 2025

Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, JPN.

Objective More patients visit oral surgery outpatient clinics from evening to night to treat persistent gingival bleeding (PGB) related to periodontal disease (PD) (PD-PGB). Since there are few reports on PD-PGB, the present study performed a detailed characterisation of this disease. Materials and methods Patients who visited our oral surgery clinic between 1 January 2014 and 31 December 2022 to treat PD-PGB without trauma.

View Article and Find Full Text PDF

Abstract: Recent clinical trials on slowing dementia progression have led to renewed focus on finding safer, more effective treatments. One approach to identify plausible candidates is to assess whether existing medications for other conditions may affect dementia risk. We conducted a systematic review to identify studies adopting a data-driven approach to investigate the association between a wide range of prescribed medications and dementia risk.

View Article and Find Full Text PDF

Introduction: Hypertension is a chronic medical state and a major determining factor for cardiovascular and renal diseases. Both genetic and non-genetic factors contribute to hypertensive conditions among individuals. The renin-angiotensin-aldosterone system (RAAS) is a major genetic target for the anti-hypertension approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!